1. Eineluoto JT, Järvinen P, Kenttämies A et al. Repeat multiparametric MRI in prostate cancer patients on active surveillance. PLoS One 2017; 12(12): e0189272.
2. Brembilla G, Dell'Oglio P, Stabile A et al. Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. Eur Radiol 2018; 28(5): 1969–1976.
3. Kozlowski P, Chang SD, Jones EC, Goldenberg SL. Assessment of the need for DCE MRI in the detection of dominant lesions in the whole gland: Correlation between histology and MRI of prostate cancer. NMR Biomed 2018; 31(3).
4. Gaunay G, Patel V, Shah P et al. Role of multi-parametric MRI, of the prostate for screening and staging: Experience with over 1500 cases. Asian J Urol 2017; 4(1): 68–74.
5. Druskin SC, Tosoian JJ, Young A et al. Incorporating prostate health index density, mri, and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU Int 2018; 121(4): 619–626.
6. Mischinger J, Kaufmann S, Russo GI et al. Targeted versus systematic robot-assisted transperineal MRI-TRUS fusion prostate biopsy. BJU Int 2018; 121(5): 791–798.
7. Schmid DT, John H, Zweifel R et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235(2): 623–628.
8. Cimitan M, Bortolus R, Morassut S et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33(12): 1387–1398.
9. Kwee SA, Coel MN, Lim J. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging. Ann Nucl Med 2012; 26(6): 501–507.
10. Graute V, Jansen N, Ubleis C et al. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39(2): 271–282.
11. Kjölhede H, Ahlgren G, Almquist H et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012; 110(10): 1501–1506.
12. Umbehr MH, Müntener M, Hany T et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 2013; 64(1): 106–117
13. Dundee PE, Hutton AC, Eden CG. [18F]fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2011; 107(1): 158–159
14. Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a 68Ga-labeled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41(1): 11–20.
15. Beer AJ, Eiber M, Souvatzoglou M et al. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 2011; 12(2): 181–191.
16. Castellucci P, Picchio M. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 2013; 40(Suppl. 1): 36–40